Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $11.8 million.

  • Gyre Therapeutics' Accumulated Expenses rose 2351.09% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 2351.09%. This contributed to the annual value of $10.6 million for FY2024, which is 1105.99% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Accumulated Expenses is $11.8 million, which was up 2351.09% from $14.9 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Accumulated Expenses high stood at $17.2 million for Q1 2025, and its period low was $708000.0 during Q3 2023.
  • Its 5-year average for Accumulated Expenses is $6.4 million, with a median of $2.5 million in 2021.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 6379.17% in 2022, then surged by 136013.89% in 2024.
  • Gyre Therapeutics' Accumulated Expenses (Quarter) stood at $1.5 million in 2021, then skyrocketed by 531.49% to $9.3 million in 2022, then increased by 28.83% to $11.9 million in 2023, then dropped by 11.06% to $10.6 million in 2024, then rose by 11.15% to $11.8 million in 2025.
  • Its Accumulated Expenses stands at $11.8 million for Q3 2025, versus $14.9 million for Q2 2025 and $17.2 million for Q1 2025.